Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
precemtabart tocentecan
- Development stage
- Phase 3
- Lead developer
- Merck KGaA
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Precemtabart tocentecan** is an investigational, CEACAM5-directed antibody-drug conjugate developed by Merck KGaA for advanced solid tumors, led by metastatic colorectal cancer. The ADC binds carcinoembryonic antigen-related cell adhesion molecule 5 on tumor cells and delivers an exatecan topoisomerase I inhibitor payload through a circulation-stable beta-glucuronide linker, causing topoisomerase I inhibition and DNA damage after tumor-cell uptake. It is being evaluated in the Phase 3 PROCEADE-CRC-03 trial in metastatic colorectal cancer, as well as earlier-stage studies in other CEACAM5-expressing solid tumors. ([merckgroup.com](https://www.merckgroup.com/en/news/precem-tct-phase-3-first-dose-21-05-2026.html))
- Brand names
- Precem-TcT
- Other names
- Precem-TcT
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on precemtabart tocentecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on precemtabart tocentecan.